MPLX LP Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by MPLX LP on March 13, 2018. The filing reports the execution of a Third Amended and Restated Distribution Agreement between the Partnership, its General Partner (MPLX GP LLC), and a group of sales agents including J.P. Morgan, Barclays, Citigroup, Merrill Lynch, RBC Capital Markets, UBS, and Wells Fargo.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed is the authorization to issue and sell common units representing limited partner interests with an aggregate offering price of up to $1,740,959,652.
Material Changes and Transaction Details
- Agreement Type: The new agreement amends and restates the Second Amended and Restated Distribution Agreement dated August 4, 2016.
- Offering Method: Sales will be conducted as "at the market offerings" under Rule 415 of the Securities Act of 1933. This includes ordinary brokers' transactions on the NYSE, other national exchanges, electronic communication networks, or block transactions.
- Principal Sales: Common units may also be sold to sales agents as principals at agreed-upon prices under separate terms agreements.
- Compensation: The Partnership will pay sales agents a commission of up to 2% of the gross sales price per common unit, plus reimbursement for certain expenses.
- Registration: The offering is conducted pursuant to a shelf registration statement on Form S-3 (No. 333-219795), declared effective on October 12, 2017.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or specific risk factors beyond the standard disclosure that the description of the agreement is qualified by reference to the full text of the agreement filed as Exhibit 1.1. No unusual items or contingencies were reported in this document.
Investor Verification Checklist
- Verify the current market price of MPLX LP common units to assess the potential dilution impact of the $1.74 billion offering capacity.
- Review the full text of the Third Amended and Restated Distribution Agreement (Exhibit 1.1) for specific termination rights and conditions.
- Confirm the status of the underlying Form S-3 registration statement (No. 333-219795) to ensure it remains effective for future sales.
- Monitor subsequent filings to determine if and when the Partnership elects to sell units under this agreement.